MX357903B - Compuestos antimicrobianos y métodos de formación y uso de los mismos.. - Google Patents

Compuestos antimicrobianos y métodos de formación y uso de los mismos..

Info

Publication number
MX357903B
MX357903B MX2013012015A MX2013012015A MX357903B MX 357903 B MX357903 B MX 357903B MX 2013012015 A MX2013012015 A MX 2013012015A MX 2013012015 A MX2013012015 A MX 2013012015A MX 357903 B MX357903 B MX 357903B
Authority
MX
Mexico
Prior art keywords
making
methods
same
antimicrobial compounds
compounds
Prior art date
Application number
MX2013012015A
Other languages
English (en)
Spanish (es)
Other versions
MX2013012015A (es
Inventor
M Duffy Erin
Chen Shili
F Kanyo Zoltan
Tang Yuanqing
Scheideman Matthew
Bhattacharjee Ashoke
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of MX2013012015A publication Critical patent/MX2013012015A/es
Publication of MX357903B publication Critical patent/MX357903B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2013012015A 2011-04-15 2012-04-11 Compuestos antimicrobianos y métodos de formación y uso de los mismos.. MX357903B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161476138P 2011-04-15 2011-04-15
US201161535118P 2011-09-15 2011-09-15
US201261610363P 2012-03-13 2012-03-13
PCT/US2012/032994 WO2012173689A2 (en) 2011-04-15 2012-04-11 Antimicrobial compounds and methods of making and using the same

Publications (2)

Publication Number Publication Date
MX2013012015A MX2013012015A (es) 2014-10-24
MX357903B true MX357903B (es) 2018-07-30

Family

ID=47357660

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012015A MX357903B (es) 2011-04-15 2012-04-11 Compuestos antimicrobianos y métodos de formación y uso de los mismos..

Country Status (21)

Country Link
US (2) US9221827B2 (enExample)
EP (2) EP2697229B1 (enExample)
JP (2) JP6317669B2 (enExample)
KR (1) KR20140065378A (enExample)
CN (2) CN109053695A (enExample)
AR (1) AR088781A1 (enExample)
AU (3) AU2012271228B2 (enExample)
BR (1) BR112013026410A2 (enExample)
CA (1) CA2833169A1 (enExample)
DK (1) DK2697229T3 (enExample)
EA (1) EA201391536A1 (enExample)
ES (1) ES2665988T3 (enExample)
HU (1) HUE036755T2 (enExample)
IL (1) IL228845A0 (enExample)
MX (1) MX357903B (enExample)
MY (1) MY173518A (enExample)
PH (1) PH12013502135A1 (enExample)
PT (1) PT2697229T (enExample)
SG (2) SG194489A1 (enExample)
TW (2) TWI656123B (enExample)
WO (1) WO2012173689A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0739738Y2 (ja) 1989-10-03 1995-09-13 三菱農機株式会社 機体転倒防止装置
US9216979B2 (en) 2009-10-16 2015-12-22 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
AU2010306646B2 (en) 2009-10-16 2016-09-01 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
PH12012500734A1 (en) 2009-10-16 2012-11-26 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
JP6317669B2 (ja) 2011-04-15 2018-04-25 メリンタ セラピューティクス インコーポレイテッド 抗菌化合物ならびにそれを作製および使用する方法
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
US9718816B2 (en) 2013-03-15 2017-08-01 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof
EP2970219B1 (en) 2013-03-15 2019-02-27 Epizyme, Inc. Carm1 inhibitors and uses thereof
AU2014315045A1 (en) * 2013-09-09 2016-03-24 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3039025A4 (en) 2013-09-09 2017-05-31 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3230259B1 (en) 2014-12-08 2024-04-03 The Research Foundation for The State University of New York Anti-fungals targeting the synthesis of fungal shingolipids
KR20180015114A (ko) * 2015-03-11 2018-02-12 멜린타 테라퓨틱스, 인크. 항미생물 화합물 및 이의 제조 및 사용 방법
CN105669519B (zh) * 2016-01-04 2018-01-05 北方民族大学 吲哚类化合物、制备方法及其作为抗耐药菌药物的应用
EP3452479A1 (en) * 2016-05-06 2019-03-13 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
WO2017193023A1 (en) * 2016-05-06 2017-11-09 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
CN109790165A (zh) 2016-05-06 2019-05-21 梅林塔治疗学股份有限公司 抗微生物剂及其制备和使用方法
WO2018232298A1 (en) 2017-06-16 2018-12-20 The Research Foundation For The State University Of New York Anti-fungals compounds targeting the synthesis of fungal sphingolipids
WO2018236692A1 (en) 2017-06-19 2018-12-27 Duffy Erin M Antimicrobials and methods of making and using same
WO2019164880A1 (en) * 2018-02-21 2019-08-29 Duffy Erin M Antimicrobials and methods of making and using same
US12152031B2 (en) 2018-06-06 2024-11-26 BioVersys AG Biodefense agents
WO2019234509A2 (en) 2018-06-06 2019-12-12 BioVersys AG Aminomethylamidine and methylamidine antimicrobial compounds
US20240239800A1 (en) * 2018-12-07 2024-07-18 BioVersys AG Pyrrolo[2,3-d]pyrimidin-2-one antimicrobial compounds
AU2020384885A1 (en) * 2019-11-13 2022-06-09 Curza Global, Llc Antimicrobial compounds and methods
CN111254091B (zh) * 2020-01-20 2022-04-19 浙江工业大学 一种嗜麦芽窄食单胞菌gyh及其在降解氯代烃类污染物中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP2873340B2 (ja) 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質tan―1057,その製造法および用途
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
GB9708611D0 (en) 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
CA2297055A1 (en) 1997-08-07 1999-02-18 Research Corporation Technologies, Inc. Antibiotic for methicillin resistant bacteria
DE19838998A1 (de) 1998-08-27 2000-03-09 Bayer Ag Neue Naturstoffderivate
EP1113008A1 (en) 1999-12-29 2001-07-04 Pfizer Products Inc. 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
DE10061542A1 (de) 2000-12-11 2002-06-13 Bayer Ag Alkanoylamino-pyrimidine
DE10061541A1 (de) 2000-12-11 2002-06-20 Bayer Ag Arylamino-Dihydropyrimidinone
DE10061537A1 (de) 2000-12-11 2002-06-20 Bayer Ag beta-Alanin-Derivate
DE10061538A1 (de) 2000-12-11 2002-06-20 Bayer Ag Ureido-Dihydropyrimidinone
US6900215B2 (en) 2000-12-15 2005-05-31 Merck Sharp & Dohme Ltd. Imidazo-pyrimidine derivatives as ligands for gaba receptors
DE10133277A1 (de) 2001-07-09 2003-01-23 Bayer Ag ß-Alanin-Derivate
DE10141271A1 (de) 2001-08-23 2003-03-06 Bayer Ag Neue Tetrahydro-1,3,5-triazin-2-on-Derivate und ihre Verwendung
DE10208256A1 (de) 2002-02-26 2003-09-04 Bayer Ag Piperidinouracile
AU2003225705A1 (en) 2003-03-07 2004-09-30 Ribapharm Inc. Cytidine analogs and methods of use
TW200509938A (en) * 2003-08-26 2005-03-16 Teijin Pharma Ltd Pyrrolopyrimidine thion derivatives
NZ544187A (en) 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
AU2007270276A1 (en) * 2006-07-03 2008-01-10 Sk Chemicals Co., Ltd. Salts of pyrrolopyrimidinone derivatives and process for preparing the same
KR20080003599A (ko) 2006-07-03 2008-01-08 에스케이케미칼주식회사 피롤로피리미디논 유도체의 겐티세이트 염 및 이의제조방법
US20100112561A1 (en) 2006-08-25 2010-05-06 Stefan Lutz Fluorescent nucleoside analogues
ES2362805T3 (es) * 2006-09-07 2011-07-13 Industrial Research Limited Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas.
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ[3,2−d]ピリミジン誘導体及びこれを有効成分とする医薬組成物
WO2008154642A2 (en) 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
KR20090098710A (ko) 2008-03-14 2009-09-17 주식회사 씨티아이바이오 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체
US20100190747A1 (en) 2009-01-27 2010-07-29 Hideo Suzuki Fused ring compound and use thereof
EP2669290A1 (en) * 2009-03-02 2013-12-04 Alnylam Pharmaceuticals Inc. Nucleic Acid Chemical Modifications
ES2620177T3 (es) 2009-10-15 2017-06-27 Guerbet Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
AU2010306646B2 (en) * 2009-10-16 2016-09-01 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
SG10201406634VA (en) * 2009-10-16 2014-11-27 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
JP6317669B2 (ja) 2011-04-15 2018-04-25 メリンタ セラピューティクス インコーポレイテッド 抗菌化合物ならびにそれを作製および使用する方法

Also Published As

Publication number Publication date
US20190322668A1 (en) 2019-10-24
EP2697229A2 (en) 2014-02-19
CA2833169A1 (en) 2012-12-20
WO2012173689A3 (en) 2013-04-04
PT2697229T (pt) 2018-04-13
AU2012271228B2 (en) 2017-04-13
DK2697229T3 (en) 2018-04-23
SG10201603027QA (en) 2016-05-30
CN103958514A (zh) 2014-07-30
TWI656123B (zh) 2019-04-11
EP3404028A1 (en) 2018-11-21
BR112013026410A2 (pt) 2017-06-27
EP2697229B1 (en) 2018-04-04
US20140163049A1 (en) 2014-06-12
US9221827B2 (en) 2015-12-29
PH12013502135A1 (en) 2022-10-26
EA201391536A1 (ru) 2014-08-29
JP6317669B2 (ja) 2018-04-25
AR088781A1 (es) 2014-07-10
KR20140065378A (ko) 2014-05-29
JP2014510788A (ja) 2014-05-01
AU2019204745A1 (en) 2019-07-18
CN103958514B (zh) 2018-07-03
JP2018115206A (ja) 2018-07-26
IL228845A0 (en) 2013-12-31
WO2012173689A2 (en) 2012-12-20
AU2012271228A1 (en) 2013-11-14
EP2697229A4 (en) 2014-09-10
TW201843154A (zh) 2018-12-16
MY173518A (en) 2020-01-30
TW201305172A (zh) 2013-02-01
MX2013012015A (es) 2014-10-24
ES2665988T3 (es) 2018-04-30
HUE036755T2 (hu) 2018-07-30
CN109053695A (zh) 2018-12-21
AU2017204803A1 (en) 2017-07-27
SG194489A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
MY173518A (en) Antimicrobial compounds and methods of making and using the same
PH12016502092A1 (en) Antimicrobial compounds and methods of making and using the same
MY176900A (en) Antimicrobial compounds and methods of making and using the same
PH12016500453A1 (en) Antimicrobial compounds and methods of making and using the same
PH12017501646A1 (en) Antimicrobial compounds and methods of making and using the same
PH12015502375B1 (en) Antimicrobial compounds and methods of making and using the same
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MY161870A (en) Antimicrobial compounds and methods of making and using the same
MX363631B (es) Composiciones y metodos para tratar infecciones bacterianas.
MX2015005753A (es) Agentes antimicrobianos.
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
IN2013MU03216A (enExample)
MX346097B (es) Derivados de difenilo sustituidos.
WO2016191695A3 (en) Treatments for obligately intracellular infections
MX2013012603A (es) Vancomicina liposomal para el tratamiento de infecciones por estafilococo aureus resistente a la meticilina (sarm).
NZ713741A (en) Antimicrobial compounds and methods of making and using the same
HK1226724A1 (en) Antimicrobial compounds and methods of making and using the same
AU2013900411A0 (en) Methods Of Treating Microbial Infections, Including Mastitis
MY171941A (en) Pharmaceutical compositions
AU2013900412A0 (en) Methods Of Treating Microbial Infections, Including Skin Infections
WO2014028780A3 (en) Antifungal compounds and methods of use

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration